Literature DB >> 31628897

Preventive Care: How Mammography Utilization Changes as Women Age.

Cindy Yuan1, Kirti Kulkarni2, Brittany Z Dashevsky3.   

Abstract

OBJECTIVE: To evaluate the impact of comorbid conditions and age on mammography use.
METHODS: We used data from the 2011 to 2015 Medical Expenditure Panel Survey, which contained records for 40,752 women over the age of 40. Use was defined as a mammogram within the previous 1 or 2 years, analyzed separately. A logit model was employed to evaluate associations between use and comorbidities and age. Statistical significance was defined by a P < .05 by two-sided test.
RESULTS: Of the 36,575 women in our study sample, 45.9%, 43.6%, 3.9%, and 5.7% reported a history of hypertension (HTN), hyperlipidemia (HLD), prior heart attack (MI), and prior stroke, respectively. Among women without a comorbid condition, there was 47.3% annual mammography use. HTN and HLD were associated with increased use (2.5 and 6.8 percentage points [pp], P< .01). In comparison, prior MI was associated with decreased annual use (-8.2 pp, P < .01). Prior stroke was not significantly associated with annual mammography (-1.5 pp, P = .42). Results were similar for biennial use. The age trend in use showed that the age with maximum screening use was approximately 60 years. DISCUSSION: Mammography use was higher in patients with HTN and HLD and lower in patients with prior MI and stroke, which may reflect differences in comorbidity-related general health care use. Use increased until it peaked around age 60. An understanding of how mammography use naturally evolves as people age may help better target specific populations and improve overall use of preventive care.
Copyright © 2019 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; breast cancer screening; comorbid conditions

Mesh:

Year:  2019        PMID: 31628897     DOI: 10.1016/j.jacr.2019.09.008

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  2 in total

1.  Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors.

Authors:  Matthew M Miller; Max O Meneveau; Carrie M Rochman; Anneke T Schroen; Courtney M Lattimore; Patricia A Gaspard; Richard S Cubbage; Shayna L Showalter
Journal:  Breast Cancer Res Treat       Date:  2021-05-25       Impact factor: 4.624

2.  MiR-526b-3p Inhibits the Resistance of Glioma Cells to Adriamycin by Targeting MAPRE1.

Authors:  Lei Qiu; Shuyuan Xing; Fuxin Lang; Qing Bao
Journal:  J Oncol       Date:  2022-02-14       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.